Empirical Finance LLC Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Empirical Finance LLC lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 47.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,297 shares of the biotechnology company's stock after selling 2,076 shares during the quarter. Empirical Finance LLC's holdings in United Therapeutics were worth $810,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cetera Investment Advisers raised its position in shares of United Therapeutics by 8.7% in the 2nd quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company's stock worth $1,964,000 after purchasing an additional 493 shares during the last quarter. SG Americas Securities LLC raised its position in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company's stock worth $535,000 after purchasing an additional 594 shares during the last quarter. CWM LLC raised its position in shares of United Therapeutics by 108.3% in the 3rd quarter. CWM LLC now owns 4,006 shares of the biotechnology company's stock worth $1,436,000 after purchasing an additional 2,083 shares during the last quarter. Ritholtz Wealth Management raised its position in shares of United Therapeutics by 14.3% in the 3rd quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company's stock worth $301,000 after purchasing an additional 105 shares during the last quarter. Finally, CHICAGO TRUST Co NA purchased a new position in shares of United Therapeutics in the 3rd quarter worth about $204,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Up 0.0 %

Shares of United Therapeutics stock traded up $0.14 during trading hours on Friday, reaching $370.58. 209,344 shares of the stock traded hands, compared to its average volume of 325,415. The company has a 50 day moving average price of $361.93 and a 200 day moving average price of $358.65. The firm has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a one year low of $211.61 and a one year high of $417.82.

Insider Buying and Selling at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 121,864 shares of company stock worth $44,516,965 in the last three months. 11.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent analyst reports. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. TD Cowen lifted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a report on Friday, November 1st. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.